3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Neoplasms
6
Solid Tumors
2
Skin Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Melanoma
2
Lung Neoplasms
2
Leukemia, B-Cell
2
Head and Neck Neoplasms
2
Breast Neoplasms
2
Vomiting
1
Urinary Bladder Neoplasms
1
Tracheal Diseases
1
TP53 Y220C Mutation
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Salivary Gland Neoplasms
1
Renal Insufficiency
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Nausea
1
Myofibroma
1
Mesothelioma
1
Interventions
Doxorubicin
5
Dacarbazine
5
Trabectedin
3
belinostat
2
PTC596
2
toripalimab
1
soblidotin
1
rucaparib
1
ridaforolimus
1
reolysin
1
pembrolizumab
1
pazopanib
1
olaratumab
1
futibatinib
1
cixutumumab
1
cemiplimab
1
anlotinib
1
Tablets
1
TTI-621
1
Rosuvastatin Calcium
1
PM 01183
1
Midazolam
1
Injections
1
Imatinib Mesylate
1
Ifosfamide
1
Fluorouracil
1
Erlotinib Hydrochloride
1
Docetaxel
1
Digoxin
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leiomyosarcoma
×
Tablets
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled